newsfilter
← Latest News
GlobeNewswire·

Septerna Highlights Business Progress and Reports Second Quarter 2025 Financial Results

Advancing Selection of Next-Generation Oral Small Molecule PTH1R Agonist for Clinical Development Initiating Phase 1 Trial for SEP-631, MRGPRX2 NAM Program, for Mast Cell Diseases Updated Cash Runway Expected to